TCRT - Alaunos Therapeutics, Inc.

3.61
0.205   5.679%

Share volume: 25,664
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$3.40
0.21
0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
8.73%
1 Month
34.20%
3 Months
-11.74%
6 Months
64.84%
1 Year
122.84%
2 Year
91.01%
Key data
Stock price
$3.61
P/E Ratio 
0.00
DAY RANGE
$3.22 - $3.70
EPS 
-$2.56
52 WEEK RANGE
$1.31 - $6.20
52 WEEK CHANGE
$132.90
MARKET CAP 
5.290 M
YIELD 
N/A
SHARES OUTSTANDING 
2.232 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.23
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$23,782
AVERAGE 30 VOLUME 
$15,182
Company detail
CEO: Kevin S. Boyle
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.

Recent news